Follow Chr. Hansen A/S

Press releases View all 426 hits

News 1 hit

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products

News   •   Aug 29, 2019 09:16 UTC

​Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.

Images View all 14 hits

Knud Vindfeldt

Knud Vindfeldt

License Creative Commons Attribution
Download
Size

259 KB • 900 x 514 px

Chr. Hansen probiotics

Chr. Hansen probiotics

License Creative Commons Attribution
Photographer / Source Chr. Hansen
Download
Size

11.1 MB • 4872 x 6496 px

Caelus logo

Caelus logo

License Creative Commons Attribution
Download
Size

113 KB • 1193 x 1224 px

World Beverage Innovation FeelGood Kefir

Documents View all 5 hits

FeelGood Kefir brochure

FeelGood Kefir brochure

Documents   •   Nov 27, 2015 12:13 UTC

Chr. Hansen DVS® FRESCO® 1000NG

Chr. Hansen DVS® FRESCO® 1000NG

Documents   •   Oct 30, 2015 08:00 UTC

L. CASEI 431® Selected summaries

L. CASEI 431® Selected summaries

Documents   •   May 21, 2015 06:57 UTC

This binder provides you with summaries of selected publications on Lactobacillus paracasei subsp. paracasei L. casei 431®.

L. CASEI 431® Handout

L. CASEI 431® Handout

Documents   •   May 21, 2015 06:57 UTC

Chr. Hansen offers multiple application forms of one of our most clinically documented Probio-Tec® strains, Lactobacillus L. casei 431®.

Contacts 3 hits

  • Commercial Development Manager
  • DKspJSviY@rwchnkr-xlhaaonsuyenrk.ctfomez
  • +45 25 46 10 07

  • Head of Investor Relations
  • dkizmaklrisw@cmhhrgf-hcxanoiseijn.kmcojhmva
  • +4553392250
Head of Investor Relations

  • Press Contact
  • Head of Media Relation
  • DKiqCAllLEmf@cwnhrlr-hwbanzqseyan.qdcoycmjq
  • +45 53 39 23 84
  • +45 45 74 76 42